Submit manuscript...
eISSN: 2373-4442


Editorial Volume 5 Issue 3

Anti-Cancer Therapy: Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in Combination with Immunotherapy

Joseph F Murphy

Charles River Laboratories, USA

Correspondence: Joseph F Murphy, Charles River Laboratories, Discovery Research Services 251 Ballard vale Street, Wilmington, MA 01887, USA, Tel  9784301729

Received: January 01, 1971 | Published: March 15, 2017

Citation: Murphy J (2017) Anti-Cancer Therapy: Non-Steroidal Anti-Inflammatory Drugs (Nsaids) in Combination with Immunotherapy. MOJ Immunol 5(3): 00156. DOI: 10.15406/moji.2017.05.00156

Download PDF


Advances in cellular and molecular immunology have provided enormous insights into the nature and consequences of interactions between tumors and immune cells. This knowledge continues to lead to strategies that marshal the immune system to treat established malignancies. The most heralded class of immuno-oncology drugs are the immune checkpoint inhibitors, which work by blocking the molecules that switch off immune cells, thus increasing tumor immunogenicity. While monoclonal antibodies, cytokines, and vaccines have shown promise individually, it is likely that the best strategy to combat cancer will be to utilize a combinatorial approach. Varying combination strategies demonstrate benefit in different patient populations. One such strategy that has received little attention is the use of non-steroidal anti-inflammatory drugs (NSAIDs), in combination with immunotherapy. This editorial briefly discusses the potential for such a strategy.


Over the past three decades, a deeper understanding of the mechanisms underlying the generation of tumor immunity has provided a framework for developing more potent immunotherapies.1 One major insight is that combinatorial approaches addressing the multiplicity of defects in the host response are likely to be required for clinical efficacy. Until recently, several immunosuppressive factors, including immune regulatory pathways/cells and tumor derived factors, have been identified that impede an effective antitumor immunotherapeutic responses.2 Strategies to break these immunosuppressive mechanisms responsible for tumor immune escape is a key goal for an effective anticancer immunotherapy. One such strategy involves the use of non-steroidal anti-inflammatory drugs (NSAIDs). The main therapeutic target of NSAIDs is the enzyme cyclooxygenase (COX), the rate limiting enzyme in the formation of prostaglandins from arachidonic acid, which is released from cell membrane stores in response to a range of stimuli. There are two isoforms of COX: COX-1 is implicated in homeostasis while COX-2 is implicated in several physiological responses including angiogenesis and metastasis.3 COX-2 is over expressed in most solid tumors, and selective COX-2 inhibitors can inhibit cell proliferation, tumor invasiveness, and angiogenesis, while simultaneously overcoming apoptosis and drug resistance as well as suppressing immune responses.4

The impact of NSAIDs, particularly COX-2 inhibitors, on reducing cancer and cancer risk, in addition to improving survival rate in several types of cancer, is well established.5 This impact is observed either alone or in combination with other therapies. Although the underlying mechanisms of these chemo-preventive effects have not yet been fully elucidated, some studies have shown that specific COX-2 inhibitors can increase the infiltration of CD4+ and CD8+ T cells to tumor sites, thus positively regulating the tumor specific host immune response. Moreover, by inhibiting prostaglandin E2 (PGE2), a key immuno-suppressor, they can also modulate the activity of T-regulatory cells, tumor-associated macrophages, and myeloid-derived suppressor cells.2

In spite of the positive results obtained with COX inhibitors alone, very few studies address the potential for NSAIDs in combination with cancer immunotherapy. One recent study reported that that administering aspirin in combination with immunotherapy could enhance the efficacy of treatment.6 Researchers reported that skin, colorectal and breast cancer can produce large amounts of PGE2 resulting in a diminution of the immune system’s ability to attack aberrant cells and allowing cancers to hide form immuno-surveillance. Pre-clinical data demonstrate that inhibiting COX synergizes with anti-PD-1 blockade in inducing eradication of tumors. This implies that COX inhibitors could be useful adjuvants for immune-based therapies in cancer.

Although relatively few studies to date have addressed the utility of using checkpoint inhibitor therapy in conjunction with NSAIDs, preliminary data suggests that this modality warrants further investigation. As combination strategies are rapidly emerging as a new paradigm for cancer therapy, utilizing COX-2 inhibition thus offers a nontoxic, readily available approach that can potentially be used in conjunction with a wide variety of other immunotherapeutic approaches.



Conflicts of interest

The authors declare no conflicts of interest.


Creative Commons Attribution License

©2017 Murphy. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.